TA Crowell, B. Danboise, A. Parikh, A. Esber, N. Dear, P. Coakley, A. Kasembeli, J. Maswai, S. Khamadi, E. Bahemana, M. Iroezindu, F. Kiweewa, J. Owuoth, J. Freeman, LL Jagodzinski, JA Malia, LA Eller, S. Tovanabutra, SA Peel, JA Ake, CS Polyak, AFRICOS Study Group. Clin Infect Dis, 2020 Aug 12; ciaa1161.doi: 10.1093/cid/ciaa1161. This email address is being protected from spambots. You need JavaScript enabled to view it.

Citation: "... From January 2013 to April 2019, adults with HIV-1 RNA >1000 copies/mL underwent ART history review and HIVDR testing upon enrollment at 12 clinics in Uganda, Kenya, Tanzania, and Nigeria. We calculated resistance scores for specific drugs and tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) using Stanford HIVDB 8.8 and SmartGene IDNS software. ..."